Literature DB >> 26281716

Abnormal Gamma Oscillations in N-Methyl-D-Aspartate Receptor Hypofunction Models of Schizophrenia.

Monika P Jadi1, M Margarita Behrens2, Terrence J Sejnowski3.   

Abstract

N-methyl-D-aspartate receptor (NMDAR) hypofunction in parvalbumin-expressing (PV+) inhibitory neurons (INs) may contribute to symptoms in patients with schizophrenia (SZ). This hypothesis was inspired by studies in humans involving NMDAR antagonists that trigger SZ symptoms. Animal models of SZ using neuropharmacology and genetic knockouts have successfully replicated some of the key observations in human subjects involving alteration of gamma band oscillations (GBO) observed in electroencephalography and magnetoencephalography signals. However, it remains to be seen if NMDAR hypofunction in PV+ neurons is fundamental to the phenotype observed in these models. In this review, we discuss some of the key computational models of GBO and their predictions in the context of NMDAR hypofunction in INs. While PV+ INs have been the main focus of SZ studies in animal models, we also discuss the implications of NMDAR hypofunction in other types of INs using computational models for GBO modulation in the visual cortex.
Copyright © 2016 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Computational models; Gamma oscillations; Inhibition; NMDA hypofunction; Parvalbumin; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26281716      PMCID: PMC4720598          DOI: 10.1016/j.biopsych.2015.07.005

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  116 in total

1.  Background gamma rhythmicity and attention in cortical local circuits: a computational study.

Authors:  Christoph Börgers; Steven Epstein; Nancy J Kopell
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-03       Impact factor: 11.205

2.  Gamma oscillation by synaptic inhibition in a hippocampal interneuronal network model.

Authors:  X J Wang; G Buzsáki
Journal:  J Neurosci       Date:  1996-10-15       Impact factor: 6.167

3.  Metastable states and quasicycles in a stochastic Wilson-Cowan model of neuronal population dynamics.

Authors:  Paul C Bressloff
Journal:  Phys Rev E Stat Nonlin Soft Matter Phys       Date:  2010-11-03

4.  A cortical circuit for gain control by behavioral state.

Authors:  Yu Fu; Jason M Tucciarone; J Sebastian Espinosa; Nengyin Sheng; Daniel P Darcy; Roger A Nicoll; Z Josh Huang; Michael P Stryker
Journal:  Cell       Date:  2014-03-13       Impact factor: 41.582

5.  Magnetoencephalographic gamma power reduction in patients with schizophrenia during resting condition.

Authors:  Lindsay Rutter; Frederick W Carver; Tom Holroyd; Sreenivasan Rajamoni Nadar; Judy Mitchell-Francis; Jose Apud; Daniel R Weinberger; Richard Coppola
Journal:  Hum Brain Mapp       Date:  2009-10       Impact factor: 5.038

Review 6.  GABA neurons and the mechanisms of network oscillations: implications for understanding cortical dysfunction in schizophrenia.

Authors:  Guillermo Gonzalez-Burgos; David A Lewis
Journal:  Schizophr Bull       Date:  2008-06-26       Impact factor: 9.306

7.  Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning.

Authors:  Christoph Kellendonk; Eleanor H Simpson; H Jonathan Polan; Gaël Malleret; Svetlana Vronskaya; Vanessa Winiger; Holly Moore; Eric R Kandel
Journal:  Neuron       Date:  2006-02-16       Impact factor: 17.173

8.  Emergent oscillations in networks of stochastic spiking neurons.

Authors:  Edward Wallace; Marc Benayoun; Wim van Drongelen; Jack D Cowan
Journal:  PLoS One       Date:  2011-05-06       Impact factor: 3.240

9.  Baseline gamma power during auditory steady-state stimulation in schizophrenia.

Authors:  Kevin M Spencer
Journal:  Front Hum Neurosci       Date:  2012-01-13       Impact factor: 3.169

10.  Chronic Ketamine Reduces the Peak Frequency of Gamma Oscillations in Mouse Prefrontal Cortex Ex vivo.

Authors:  James M McNally; Robert W McCarley; Ritchie E Brown
Journal:  Front Psychiatry       Date:  2013-09-17       Impact factor: 4.157

View more
  49 in total

1.  Deletion of the Mitochondrial Matrix Protein CyclophilinD Prevents Parvalbumin Interneuron Dysfunctionand Cognitive Deficits in a Mouse Model of NMDA Hypofunction.

Authors:  Aarron Phensy; Kathy L Lindquist; Karen A Lindquist; Dania Bairuty; Esha Gauba; Lan Guo; Jing Tian; Heng Du; Sven Kroener
Journal:  J Neurosci       Date:  2020-06-30       Impact factor: 6.167

2.  Altered CREB Binding to Activity-Dependent Genes in Serine Racemase Deficient Mice, a Mouse Model of Schizophrenia.

Authors:  Darrick T Balu; Joseph T Coyle
Journal:  ACS Chem Neurosci       Date:  2017-11-27       Impact factor: 4.418

Review 3.  Altering the course of schizophrenia: progress and perspectives.

Authors:  Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger
Journal:  Nat Rev Drug Discov       Date:  2016-03-04       Impact factor: 84.694

4.  Parvalbumin-containing GABA cells and schizophrenia: experimental model based on targeted gene delivery through adeno-associated viruses.

Authors:  Marta U Woloszynowska-Fraser; Peer Wulff; Gernot Riedel
Journal:  Behav Pharmacol       Date:  2017-12       Impact factor: 2.293

5.  Diverse Effects on M1 Signaling and Adverse Effect Liability within a Series of M1 Ago-PAMs.

Authors:  Jerri M Rook; Masahito Abe; Hyekyung P Cho; Kellie D Nance; Vincent B Luscombe; Jeffrey J Adams; Jonathan W Dickerson; Daniel H Remke; Pedro M Garcia-Barrantes; Darren W Engers; Julie L Engers; Sichen Chang; Jarrett J Foster; Anna L Blobaum; Colleen M Niswender; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley
Journal:  ACS Chem Neurosci       Date:  2017-01-10       Impact factor: 4.418

6.  Cholinergic Neurons of the Medial Septum Are Crucial for Sensorimotor Gating.

Authors:  Junghee Jin; Jia Cheng; Ko-Woon Lee; Bushra Amreen; Kathryn A McCabe; Clark Pitcher; Thomas Liebmann; Paul Greengard; Marc Flajolet
Journal:  J Neurosci       Date:  2019-04-26       Impact factor: 6.167

7.  Dynamic brain network reconfiguration as a potential schizophrenia genetic risk mechanism modulated by NMDA receptor function.

Authors:  Urs Braun; Axel Schäfer; Danielle S Bassett; Franziska Rausch; Janina I Schweiger; Edda Bilek; Susanne Erk; Nina Romanczuk-Seiferth; Oliver Grimm; Lena S Geiger; Leila Haddad; Kristina Otto; Sebastian Mohnke; Andreas Heinz; Mathias Zink; Henrik Walter; Emanuel Schwarz; Andreas Meyer-Lindenberg; Heike Tost
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-17       Impact factor: 11.205

8.  Neonatal Ethanol Disturbs the Normal Maturation of Parvalbumin Interneurons Surrounded by Subsets of Perineuronal Nets in the Cerebral Cortex: Partial Reversal by Lithium.

Authors:  Mariko Saito; John F Smiley; Maria Hui; Kurt Masiello; Judith Betz; Maria Ilina; Mitsuo Saito; Donald A Wilson
Journal:  Cereb Cortex       Date:  2019-04-01       Impact factor: 5.357

Review 9.  Electrophysiological Endophenotypes for Schizophrenia.

Authors:  Emily M Owens; Peter Bachman; David C Glahn; Carrie E Bearden
Journal:  Harv Rev Psychiatry       Date:  2016 Mar-Apr       Impact factor: 3.732

10.  Prefrontal Cortex-Mediated Impairments in a Genetic Model of NMDA Receptor Hypofunction Are Reversed by the Novel M1 PAM VU6004256.

Authors:  Michael D Grannan; Catharine A Mielnik; Sean P Moran; Robert W Gould; Jacob Ball; Zhuoyan Lu; Michael Bubser; Amy J Ramsey; Masahito Abe; Hyekyung P Cho; Kellie D Nance; Anna L Blobaum; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Carrie K Jones
Journal:  ACS Chem Neurosci       Date:  2016-10-05       Impact factor: 4.418

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.